Neurology News

The FDA approved an updated label for Aduhelm that emphasizes the disease stages examined in the clinical trials, specifically stating that the agent should be initiated in patients with mild cognitive impairment or dementia.

New research suggests a letter may be all that it takes to lower the number of telehealth no-shows among older patients, even during a pandemic.

Along with retirement and personal investment accounts, the family home and its equity are often a physician’s most valuable asset.

More than 2.4 million ED visits and 700,000 hospitalizations among adults aged 65 years and older were caused by injuries from falls, motor vehicle accidents, opioid overdoses and self-harm in 2018, according to data in MMWR.

Differences in sources of recruitment, reasons for screen failure and overall probability of eligibility occurred across racial/ethnic groups included in a large preclinical Alzheimer’s disease trial conducted in North America.

Consecutive sleep loss predicted poorer daily affective and physical well-being among a large sample of U.S. adults, with well-being declining after one night of sleep loss, according to findings published in Annals of Behavioral Medicine.

The FDA granted orphan drug designation to iniparib for treatment of malignant glioma, according to the agent’s manufacturer.

Patients with glioma who completed the 8-week GLioma Atkins-based Diet experienced “meaningful” ketonuria and significant systemic and cerebral metabolic changes, according to results from a small study published in Neurology.

Extremely preterm infants with prolonged exposure to opioids and benzodiazepines experienced an increased risk for worse neurodevelopmental outcomes at 2 years’ corrected age, according to results from a cohort study.

Longer exposure to endogenous estrogen is associated with increased levels of Alzheimer’s disease biomarkers in women, according to a study published in Menopause.